Dr. Agarwal's Health Care Limited was incorporated at Chennai, Tamil Nadu as a public limited company under the Companies Act, 1956, pursuant to the certificate of incorporation dated April 19, 2010, issued by the RoC and commenced operations pursuant to the certificate for commencement of business dated May 29, 2010, issued by the RoC.

Dr. Agarwal's Health Care provides a comprehensive range of eye care services, including cataract, refractive and other surgeries; consultations, diagnoses and non-surgical treatments; and sell opticals, contact lenses and accessories, and eye care related pharmaceutical products. The company had a market share of around 25% of the total eye care service chain market in India during the Financial Year 2024. The company categorizes its Facilities as Primary Facilities [which are non-surgical eye care facilities); Secondary Facilities (which are surgical Facilities); and Tertiary Facilities (which are super-specialty surgical Facilities and include three centres of excellence (COEs)], depending upon the nature of services provided. The company’s business operations are structured as a “hub and spoke” model, which enables it to build a scalable and accessible platform for the continued growth of its business. 

The company’s Primary Facilities provide initial eye care diagnosis and clinical investigation services. The Secondary Facilities at its spokes provide select services including cataract surgeries and clinical investigations while its Tertiary Facilities have super-specialty surgical capabilities including retinal, corneal, and refractive surgeries. The company’s COEs, in addition to being Tertiary Facilities, also offer academic programs in ophthalmology and provide continuous training for its doctors, optometrists, and counsellors, among others. Its integrated hub and spoke model enable deeper geographic penetration, allowing greater accessibility to patients while driving efficiency of critical resources across the network. 

Business area of the company

The company and its subsidiaries/associate are primarily engaged in running, owning and managing eye care hospitals, opticals, pharmacies, etc.

Awards and accreditation

• 2023: AHCL was awarded as ‘One of the Best Healthcare Brands - 2023’ at The Economic Times Best Healthcare Brands 2023.
• 2024: ‘Best Employer 2024-2025 - Tamil Nadu’ at the 19th Employer Branding Awards.
• 2022: AHCL was awarded ‘E4M Pride of India Brands’ at the Best of Bharat Awards 2022.
• 2022: AHCL was awarded the ‘Best Eye Hospital’ at the Pulse Healthcare Awards, Tamil Nadu.
• 2023: AHCL was ranked as ‘India’s Most Trusted Eye Hospitals category’ in the Trust Research Advisory’s Brand Trust Report, India Study 2023.
• 2024:  AHCL was awarded the Bronze award for ‘Digital Initiative for Patient Education’ award at the Smart Hospitals and Diagnostic Awards, 2024.
• 2024: AHCL was awarded the ‘Best Use of TV in Healthcare - Gold’ and ‘Best Use of Print in Healthcare - Silver’ awards at the annual e4m Indian Marketing Awards, 2024 - South.

History and milestones

• 2010: Incorporation of the company. 
• 2010: Entry into the Telangana (formerly a part of Andhra Pradesh) and Karnataka markets by entering into lease agreements for setting up eye clinics.
• 2011: Investment by EILSF SPV 3 in the company. 
• 2012: Entry into the Africa market by entering into an agreement with Dr, Amelia Buque to jointly promote eye hospitals and other health care related services in Mozambique.
• 2017: Entry into the Maharashtra market through the acquisition of hospital facilities in Maharashtra.
• 2019: Investment by Claymore Investments (Mauritius), an indirect wholly owned subsidiary of Temasek Holdings (Private) Limited and Value Growth Investment Holdings Pte. Ltd in the company through subscription of equity shares. 
• 2019: Subscription of NCDs by British International Investment (formerly known as CDC Group PLC) in the company.
• 2021: The Company launched its 100th eye care facility. 
• 2022: Investment by TPG Capital’s Hyperion Investments Pte. Ltd. and Arvon Investments Pte. Ltd., an indirect wholly owned subsidiary of Temasek Holdings (Private) Limited in the Company through subscription of equity shares. 
• 2022: Entry into the Jammu market through the acquisition of Dr. Sood eye care practices from Dr. Rohan and Raj Deep Sood. 
• 2022: Strengthened presence in the Gujarat market through acquisition of the eye care business from Prizma Eyecare LLP, Dr. Sanjay Vallabhai Savani and Dr. Ashish P. Gusani
• 2023: Strengthened presence in the Punjab market through the acquisition of Punjab Eye Hospital from Dr. Gurpal Singh.
• 2024: Entry in the Uttar Pradesh market through the acquisition of an eye care business in Varanasi. Expanded its` presence in Punjab market by acquisition of Dr Thind Eye Care Private Limited.